DHTKD1 and cancer: In early therapeutic trials, most of these adenoviruses were replication-incompetent, but currently the majority of therapeutic applications exploit promoters that can drive adenovirus E1A and E1B gene expression in a cancer-specific manner resulting in conditional replication [60,68,69,70,71].